Sirolimus-Based Immunosuppression as GvHD Prophylaxis after Bone Marrow Transplantation for Severe Aplastic Anaemia: A Case Report and Review of the Literature
Congenital or acquired severe aplastic anaemia (SAA) is cured by bone marrow transplantation (BMT) from a histocompatible leukocyte antigen- (HLA-) identical sibling. The best conditioning regimen is cyclophosphamide (CTX) with or without antithymocyte globulin (ATG), followed by short-term methotre...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2015/321602 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849683361164951552 |
|---|---|
| author | Katia Perruccio Elena Mastrodicasa Francesco Arcioni Ilaria Capolsini Carla Cerri Grazia Gurdo Maurizio Caniglia |
| author_facet | Katia Perruccio Elena Mastrodicasa Francesco Arcioni Ilaria Capolsini Carla Cerri Grazia Gurdo Maurizio Caniglia |
| author_sort | Katia Perruccio |
| collection | DOAJ |
| description | Congenital or acquired severe aplastic anaemia (SAA) is cured by bone marrow transplantation (BMT) from a histocompatible leukocyte antigen- (HLA-) identical sibling. The best conditioning regimen is cyclophosphamide (CTX) with or without antithymocyte globulin (ATG), followed by short-term methotrexate (MTX) and cyclosporine A (CsA) to prevent graft-versus-host disease (GvHD). In our pediatric oncology-hematology unit, a 5-year-old girl with SAA was treated with two BMT from the same HLA-identical sibling donor. Severe CsA-induced adverse events (severe hypertension and PRES) after the first BMT led necessarily to CSA withdrawal. Alternative immunosuppressive treatment for GvHD prevention as tacrolimus and mycophenolate were not tolerated by our patient because toxicity > grade II. For this reason we decided to administrate sirolimus alone as GvHD prophylaxis and to prevent disease relapse after the rescue BMT. Here we report the successful use of sirolimus alone for GvHD prophylaxis after the second transplant in a pediatric BMT setting for SAA. |
| format | Article |
| id | doaj-art-dbe08da73faa41b6a2cbcffddf6f003d |
| institution | DOAJ |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-dbe08da73faa41b6a2cbcffddf6f003d2025-08-20T03:23:56ZengWileyCase Reports in Hematology2090-65602090-65792015-01-01201510.1155/2015/321602321602Sirolimus-Based Immunosuppression as GvHD Prophylaxis after Bone Marrow Transplantation for Severe Aplastic Anaemia: A Case Report and Review of the LiteratureKatia Perruccio0Elena Mastrodicasa1Francesco Arcioni2Ilaria Capolsini3Carla Cerri4Grazia Gurdo5Maurizio Caniglia6Pediatric Oncology Hematology Unit, Perugia General Hospital, Località Sant’Andrea delle Fratte, 06156 Perugia, ItalyPediatric Oncology Hematology Unit, Perugia General Hospital, Località Sant’Andrea delle Fratte, 06156 Perugia, ItalyPediatric Oncology Hematology Unit, Perugia General Hospital, Località Sant’Andrea delle Fratte, 06156 Perugia, ItalyPediatric Oncology Hematology Unit, Perugia General Hospital, Località Sant’Andrea delle Fratte, 06156 Perugia, ItalyPediatric Oncology Hematology Unit, Perugia General Hospital, Località Sant’Andrea delle Fratte, 06156 Perugia, ItalyPediatric Oncology Hematology Unit, Perugia General Hospital, Località Sant’Andrea delle Fratte, 06156 Perugia, ItalyPediatric Oncology Hematology Unit, Perugia General Hospital, Località Sant’Andrea delle Fratte, 06156 Perugia, ItalyCongenital or acquired severe aplastic anaemia (SAA) is cured by bone marrow transplantation (BMT) from a histocompatible leukocyte antigen- (HLA-) identical sibling. The best conditioning regimen is cyclophosphamide (CTX) with or without antithymocyte globulin (ATG), followed by short-term methotrexate (MTX) and cyclosporine A (CsA) to prevent graft-versus-host disease (GvHD). In our pediatric oncology-hematology unit, a 5-year-old girl with SAA was treated with two BMT from the same HLA-identical sibling donor. Severe CsA-induced adverse events (severe hypertension and PRES) after the first BMT led necessarily to CSA withdrawal. Alternative immunosuppressive treatment for GvHD prevention as tacrolimus and mycophenolate were not tolerated by our patient because toxicity > grade II. For this reason we decided to administrate sirolimus alone as GvHD prophylaxis and to prevent disease relapse after the rescue BMT. Here we report the successful use of sirolimus alone for GvHD prophylaxis after the second transplant in a pediatric BMT setting for SAA.http://dx.doi.org/10.1155/2015/321602 |
| spellingShingle | Katia Perruccio Elena Mastrodicasa Francesco Arcioni Ilaria Capolsini Carla Cerri Grazia Gurdo Maurizio Caniglia Sirolimus-Based Immunosuppression as GvHD Prophylaxis after Bone Marrow Transplantation for Severe Aplastic Anaemia: A Case Report and Review of the Literature Case Reports in Hematology |
| title | Sirolimus-Based Immunosuppression as GvHD Prophylaxis after Bone Marrow Transplantation for Severe Aplastic Anaemia: A Case Report and Review of the Literature |
| title_full | Sirolimus-Based Immunosuppression as GvHD Prophylaxis after Bone Marrow Transplantation for Severe Aplastic Anaemia: A Case Report and Review of the Literature |
| title_fullStr | Sirolimus-Based Immunosuppression as GvHD Prophylaxis after Bone Marrow Transplantation for Severe Aplastic Anaemia: A Case Report and Review of the Literature |
| title_full_unstemmed | Sirolimus-Based Immunosuppression as GvHD Prophylaxis after Bone Marrow Transplantation for Severe Aplastic Anaemia: A Case Report and Review of the Literature |
| title_short | Sirolimus-Based Immunosuppression as GvHD Prophylaxis after Bone Marrow Transplantation for Severe Aplastic Anaemia: A Case Report and Review of the Literature |
| title_sort | sirolimus based immunosuppression as gvhd prophylaxis after bone marrow transplantation for severe aplastic anaemia a case report and review of the literature |
| url | http://dx.doi.org/10.1155/2015/321602 |
| work_keys_str_mv | AT katiaperruccio sirolimusbasedimmunosuppressionasgvhdprophylaxisafterbonemarrowtransplantationforsevereaplasticanaemiaacasereportandreviewoftheliterature AT elenamastrodicasa sirolimusbasedimmunosuppressionasgvhdprophylaxisafterbonemarrowtransplantationforsevereaplasticanaemiaacasereportandreviewoftheliterature AT francescoarcioni sirolimusbasedimmunosuppressionasgvhdprophylaxisafterbonemarrowtransplantationforsevereaplasticanaemiaacasereportandreviewoftheliterature AT ilariacapolsini sirolimusbasedimmunosuppressionasgvhdprophylaxisafterbonemarrowtransplantationforsevereaplasticanaemiaacasereportandreviewoftheliterature AT carlacerri sirolimusbasedimmunosuppressionasgvhdprophylaxisafterbonemarrowtransplantationforsevereaplasticanaemiaacasereportandreviewoftheliterature AT graziagurdo sirolimusbasedimmunosuppressionasgvhdprophylaxisafterbonemarrowtransplantationforsevereaplasticanaemiaacasereportandreviewoftheliterature AT mauriziocaniglia sirolimusbasedimmunosuppressionasgvhdprophylaxisafterbonemarrowtransplantationforsevereaplasticanaemiaacasereportandreviewoftheliterature |